Bioinformatics 2004

• Industry Impact and Outlook -

26th & 27th May 2004, Marriott Kensington, London

Effective use of bioinformatic systems can drastically reduce drug discovery and development timescales

• By using information technology and software tools

to analyse gene sequences, genotypes that correspond to certain medical conditions may be identified.

• Informatics can then lead to the discovery of potential

molecular targets and subsequently the development and design of drugs far more rapidly than previously possible. Bioinformatics 2004 will provide a unique overview of the technologies available and in development:

***Latest Confirmed Speaker: Dr Stephen Dobson, Pharmacogenomics Informatics Scientist, Pfizer***

Key themes will include:

• In depth analysis and strategies to improve information-flow
• Tactics for knowledge management and evolution of innovative informatic solutions
• Finding the best ways to handle e-clinical data and upcoming opportunities in this market
• Data analysis and integration: pointers on data mining, in silico research and use of informatic tools
• Case studies of informatic systems: learn from leaders in the industry
• Current market and outlook: genomics, proteomics and pharmacogenomics

Industry Leading speakers confirmed at this event:

• Dr. Mark Swindells, Chief Scientific Officer, Inpharmatica
• Dr. Charlie Hodgman, Chair of Bioinformatics, Uni. Nottingham & Midlands Centre for Integrative Biology & Former Senior Informatics Leader, GSK
• Dr Luca Casareto, Director Bioinformatic Solutions, Invitrogen Bioinformatics (Informax)
• Robin Clark, Managing Consultant, IBM Business Consulting Services
• Dr. Krister Kristianson, Director of Clinical Research, Merck
• Hani Kamel, Quality and Security Advisor, Novo Nordisk
• Dr. Richard Scott, Director of Technology Development, De Novo Pharmaceuticals
• Kevin Wandryk, VP Marketing & Business Development, Silicon Genetics
• Dr. Ulrich Meier, Industry Marketing Manager Life Sciences, Sun Microsystems
• Dr. Kal Ramnarayan, Vice President and CSO, Cengent Therapeutics
• Thure Etzold, Senior VP Bioinformatics, LION Bioscience
• David Lovell, Reader in Medical Statistics, University of Surrey & Former Associate Director, European Head of Statistical Support to Clinical Pharmacology, Pfizer

Who Should attend? (by job title)

• Global Head, Informatics & Knowledge Management
• Director of Medical Informatics
• Director of Discovery Research Informatics
• Head of Advanced Computing
• Head of Global IT Management
• Head/ Director of Bioinformatics
• Head of Datamining and Visualisation
• Senior Informatics Leader
• Head of Life Science Informatics
• Senior Scientist, Genomic Collaborations
• European Applications Specialist
• Director, Discovery Bioinformatics
• European Manager, Statistics & Information Science
• Director, IT Discovery Pharmaceuticals
• Director, Global Information Solutions
• Head of Informatics

Please find below the conference agenda. To book your place at Bioinformatics 2004 simply give me a quick ring or email me stating whether you require a single place or a group booking

• PRICING -

Attend the: ** Conf. + pre conf. workshop GBP 1600.00 Plus VAT ** Conference only Fee: GBP1299.00 Plus VAT ** Pre conference workshop only Fee: GBP 650.00 Plus VAT

• BOOKINGS -

Booking is easy, simply contact Lorraine on: Telephone: +44 (0)20 8767 6711 Fax: +44 (0)20 8767 5001 Email: mailto:lorraine.lescure@visiongain.com Terms and conditions apply - see below. I look forward to hearing from you soon.

Regards,

Lorraine Lescure Account Manager Visiongain b2b Conferences Tel: +44 (0) 20 8767 6711 http://www.b2b-conferences.com mailto:lorraine.lescure@visiongain.com

Sponsorship Opportunities> This event will provide unrivalled opportunities to promote your brand to an audience of senior level delegates. Decision makers from all aspects of the Bioinformatics industry will be in attendance, what better way to elevate your product? We are continually recognised for providing innovative and effective means to support your marketing requirements through sponsorship and exhibitions at our leading events. Options include:

• Full Conference Sponsorship
• Exhibition Stand/Booth
• Promotional Inserts
• Delegate Bag Sponsor
• Cocktail Reception Sponsor

Whatever your budget, whatever your requirements we can find you a way to place your brand at Bioinformatics 2004.

***Agenda***

Pre-Conference Interactive Workshop Successful Licensing and Business Development Tuesday 25th May 2004

Workshop Leaders: Mrs. Sharon Finch and Prof. Bill Dawson, Medius Associates

Topics Under discussion:

• Logistics and planning the due diligence process
• Scientific and regulatory due diligence
• Intellectual property rights, legal and corporate due diligence
• Commercial and financial issues
• Logistics- planning and negotiation
• Preparation
• Understanding the third party
• Team roles and negotiation styles
• Negotiation tactics

DAY 1 Wednesday 26th May 2004

Conference Chairman David Lovell Reader in Medical Statistic University of Surrey

9:00 Registration and coffee

9:30 Opening remarks from the Chair

STRATEGIC PLANNING

9:40 How to Transform Data into Commercially Valuable Information *> Overcoming challenges faced by the pharmaceutical industry *> Key organisational strategies: meeting the needs of the pharmaceutical vs biotech *> What is the optimal structure for informatics in R&D? *> How to use informatic services to facilitate drug discovery and development *> A guide to transforming sequence data into validated drug targets Dr. Mark Swindells Chief Scientific Officer Inpharmatica

10:20 Aiding Business Strategy: An Information-Flow Model *> Model: structured map of pharmaceutical information, depicting issues faced *> Strategies for reducing costs through portfolio management and interconnectivity *> Proposals for using information mechanisms for increased efficiency *> Model for biotech:

• where a novel technology might impact upon and improve the

R&D process

• where can service/ information providers position themselves for

maximum benefit *> Key thinking for business development Dr. Charlie Hodgman Chair of Bioinformatics Uni. Nottingham and Directorship of the Midlands Centre for Integrative Biology

11:00 Morning Coffee

11:20 Pointers for Choosing the Best Partnership for You *> Licensing out products following pre-clinical development *> How to identifying the correct product to license in *> Gaining or giving access to technologies, which will be the best for you? *> Recommendations on which route to take: comparison of different agreements Panel Discussion and Questions

KNOWLEDGE MANAGEMENT

12:00 Procedures in Driving Data Workflow Integration for Effective Information Management *> How to alleviate the bottlenecks in the life science pipeline

• better investment in tools and applications

*> Can better integration techniques ease the burden of delivering faster processes? *> Large bioinformatic systems versus integrated discrete solutions *> Informax bioinformatics solutions for workflow optimisation and pipeline integration Dr Luca Casareto Director Bioinformatic Solutions Invitrogen Bioinformatics (Informax)

12:40 Lunch

DATA ANALYSIS AND INTEGRATION

14:00 In silico Research: Bridging the gap between Drug Discovery and Development *> How to use in silico tools for rational chemical design *> Advantages of in silico drug discovery *> Potential enhancement of the overall R&D productivity> *> Challenges of in silico biology technology for tomorrow *> The future of simulation - Systems Biology? Dr. Richard Scott Director of Technology Development De Novo Pharmaceuticals

14:40 Informatics Software Market: Breaking Constraints and Handling Competition *> Area sectors: specialising in software packages for visualising, interpreting and analysing data *> How to overcome constraints of this niche market

• limited number of customers
• diverse informatic needs of clients

*> How to handle direct competition

• free or publicly available software and tools
• direct competition from academic institutions
• small startups v large companies

Kevin Wandryk VP Marketing & Business Development Silicon Genetics

15:20 Afternoon Tea

HANDLING E-CLINICAL DATA

15:40 Strategies for Reducing the Time and Cost of Running Trials, whilst increasing the Quality of Data *> Difficulties faced in drug development *> Turning challenges to opportunities *> How to simplify and automate trial processes, for example:

• by transforming trial management
• taking EDC to the next level
• implementing an efficient archival strategy

*> A holistic approach to clinical data Robin Clark Managing Consultant IBM Business Consulting Services

16:20 Questions and Discussion

16:40 Close of Day One

DAY 2 Thursday 27th May 2004

Conference Chairman David Lovell Reader in Medical Statistic University of Surrey

9:00 Registration and Coffee

9:30 Opening remarks from the chair

9:40 Electronic Medical Records or e-source: how to cut your monitoring cost in half by no more SDV, no more data entry no missed data *> EMR's - a challenge to the conduct of clinical trials *> How to deal with its rapid entry into the hospital and medical records *> Increased complications in the access to the source: security and privacy of the hospital system *> How to use opportunities in the market Dr. Krister Kristianson Director of Clinical Research Merck

10:20 Data Standards and the FDA: Overcoming the Challenges Associated with E-Clinical Trials *> Evaluating FDA acceptance of new technologies in clinical trials *> Implementation of e-signatures *> Reconciliation with HL7 standards *> Using clinical data interchange standards for the development of e-clinical trials Charles Jaffe Director of Medical Informatics AstraZeneca

11:00 Morning Coffee

11:20 Key Tactics to Enhance Global Data Security *> Meeting universal requirements: what regulatory problems could arise? *> Overcoming the scientific problems that can arise from poor security *> Recommendations for enabling global security to fit unobtrusively into the clinical environment *> Proposals to ensure clinical data security over the web Hani Kamel Quality and Security Advisor Novo Nordisk

PRACTICAL BIOINFORMATICS: IN THE INDUSTRY

12:00 CASE STUDY: Grid Computing and its Impact on Your Network *> Grid computing solutions- tackles complex computer intensive tasks quickly and cost-effectively *> Three basic deployment types: cluster grids, enterprise grids, and global grids *> What benefits do grids delivery that traditional computing models are not able to? *> Sun's bio-grid strategy *> Sun infrastructure solutions: transforming technology into business results *> Deploying grid computing for a competitive advantage Dr. Ulrich Meier Industry Marketing Manager Life Sciences Sun Microsystems

12:40 Lunch

14:00 CASE STUDY: Accelerating Your Drug Discovery with Genes to Leads *> How can genes to leads deliver selective hits in as little as 60 days? *> Key differentiators from alternative drug discovery approaches *> Features and benefits of proprietary technology *> Success in discovering potent small-molecule leads for anthrax infection and PTP1B> *> Genes to Leads success summary Dr. Kal Ramnarayan Vice President and CSO Cengent Therapeutics

14:40 CASE STUDY: SRS Gateway for Oracle, Reducing the Challenges for the Life Science Industry *> SRS and the oracle database *> What are the benefits of combining the power of two industry-leading platforms *> Experience of SRS collaborations, the SRS evolution *> The drive for drug discovery, a working progress Thure Etzold Senior VP Bioinformatics LION Bioscience

15:20 Afternoon Tea

PROTEOMICS

15:40 Managing Collection, Analysis and Interpretation of Data from Functional Proteomics *> Data from functional proteomics: how to effectively and efficiently manage it *> Statistical input into the design, analysis and interpretation of functional proteomic studies *> Achieving synergy between bioinformatics and statistics *> Linking analysis of pharmacogenomic data into drug discovery and development David Lovell Reader in Medical Statistics University of Surrey

16:20 Pharmacogenomics in drug development

• Impact of pharmacogenomics on the cost of drug development and clinical trials
• Potential value of pharmacogenomics in clinical trials
• Incorporating pharmacogenomics into clinical trials: is it possible?
• Opportunities present
• The challenge of sample collection and data delivery.

Dr Stephen Dobson Pharmacogenomics Informatics Scientist Pfizer

17:00 Questions and Discussion

17:20 Chairman Summation

17:30 Close of Conference

Visiongain/B2B Conferences produce a range of timely business information material, if you wish to receive information of new products, simply reply to this email with ' New Products info' in the subject box

Terms & Conditions NB - Due to high demand, we do not 'reserve' or 'hold' places - a request for an invoice to be raised will be treated as an official booking and will be subject to the cancellation policy as outlined below. Cancellations/substitutions and name changes: All bookings carry a 50% liability after the booking has been made, by post fax, email or web. There will be no refunds for cancellations received on or after one month before the start of the conference (e.g. cancellation on or after 20th January for a conference starting on 20th February). If you decide to cancel after this date the full invoice remains payable. Conference notes, which are available on the day, will be sent to you. Unfortunately we are not able to transfer places between conferences and executive briefings. However if you are unable to attend the event you may make a substitution/name change at any time as long as we are informed in writing by e-mail, fax or post. Name changes and substitutions must be from the same company and are not transferable between companies or countries.

Indemnity: visiongain Ltd reserve the right to change the conference/executive briefing content, timing, speakers or venue without notice. The event may be postponed or cancelled due to acts of terrorism, war, extreme weather conditions, industrial action, acts of God or any event beyond the control of visiongain Ltd. If such a situation arises we will endeavour to reschedule the event. However, visiongain Ltd cannot be held responsible for any cost, damage or expenses, which may be incurred by the customer as a consequence of the event being postponed or cancelled. We therefore strongly advise all customers to take out insurance to cover the cost of the registration, travel and expenses. To unsubscribe please reply with unsubscribe in the subject line. Data protection: Visiongain Ltd gathers and manages data in accordance with the Data Protection Act 1998. Information contained about you may be used to update you on visiongain Ltd products and services via post, telephone, fax or email, unless you state otherwise. We ma> y share your data with external companies offering complimentary products or services. If you wish your details to be amended, suppressed or not passed onto any external third party, please send your request to the Database Manager, visiongain Ltd, 40 Tooting High Street, London, SW17 0RG. Alternatively, you can visit our website www.visiongain.com <http://www.visiongain.com/> and amend your details. Please allow approximately 30 days for your removal or update request, you may receive additional pieces of communication from visiongain Ltd during the transitional period, whilst the changes come into effect.

#####################################################################################

This email has been scanned by MailMarshal, an email content filter.

#####################################################################################